Navigation Links
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes

DEERFIELD, Ill. and OSAKA, Japan, Aug. 28 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

The alogliptin New Drug Application (NDA) was submitted in December 2007, and in the complete response for alogliptin dated June 26, 2009, the FDA requested an additional CV safety trial that satisfies the criteria outlined in the December 2008 "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes." The EXAMINE study is designed to comply with this Guidance.

"Takeda received FDA agreement to the design of the CV study and we are pleased to move forward with the study and collecting additional safety data so that the FDA can continue the review of the alogliptin NDA," said Nancy Joseph-Ridge, M.D., General Manager, Pharmaceutical Development Division. "We are committed to conducting this study to satisfy the CV safety requirements, leading to the enhancement of the product profile of alogliptin. While this trial is dependent on the occurrence of CV events, at this point we anticipate that we will be able to submit interim results to the FDA approximately two years after the study begins that will meet the FDA Guidance criteria for drug approval."

Outline of the EXAMINE Trial

    Title:             A Multicenter, Randomized, Double-Blind, Placebo-
                       Controlled Study to Evaluate Cardiovascular Outcomes
                       Following Treatment with Alogliptin in Addition to
                       Standard of Care in Subjects with Type 2 Diabetes and
                       Acute Coronary Syndrome

    Study Start:       September 2009

    Study Completion:  December 2014

    No. of Patients:   Approximately 5,400

    Primary Outcome:   Time from randomization to the occurrence of the
                       Primary Major Adverse Cardiac Events defined as
                       a composite of cardiovascular death, nonfatal
                       myocardial infarction and nonfatal stroke

    Secondary Outcome: Time from randomization to the occurrence of the
                       Secondary Major Adverse Cardiac Events defined
                       as a composite of cardiovascular death, nonfatal
                       myocardial infarction, nonfatal stroke and urgent
                       revascularization due to unstable angina

    Study Sites:       Approximately 1,000 sites in the U.S., Europe, Asia

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site,

About Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
11. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015  SeraCare Life Sciences, a leading ... that the company,s precision medicine business unit has launched ... materials for next-generation sequencing (NGS)-based tumor profiling assays.  The ... the same mixture of mutations in key oncogenes and ... AF20 mix , but is offered at five additional ...
(Date:10/13/2015)... 2015  Graduate students across the country, with ... will soon have the opportunity to learn about ... drug discovery and development process. Eli Lilly and ... 10 leaders from academic institutions to create an ... of Drug Development."  Lilly will formally unveil the ...
(Date:10/13/2015)... WASHINGTON , Oct. 13, 2015 /PRNewswire/ ... the first-ever direct-to-consumer laboratory home testing kit ... and digital technologies provide an unparalleled, detailed ... of breast milk—fats, proteins, carbs and key ... digital portal for personal health tracking.  In addition, ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... management services, today announced its partnership with WPC Healthcare , a provider ... systems and organizes the data into an aggregated data repository necessary to perform ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits ... GPUG Summit and NAVUG Summit are independent user conferences designed and led by ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... ... A child without a healthy mouth is much more likely to have ... system, has joined with Global Dental Relief (GDR) to help bring dental ... purchased, SmileCareClub will donate one clinic visit to a child in Kenya. , “When ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... targets the unique health needs of new moms. Postnatal Omega-3, which has ... ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. This breakthrough ...
Breaking Medicine News(10 mins):